Responses
Poster Presentation
Superiority of dendritic cell vaccine vs tumor cell vaccine: survival by stratification subsets in MACVAC randomized Phase II trial of patient-specific vaccines utilizing antigens from autologous melanoma tumor cell lines
Compose a Response to This Article
Other responses
No responses have been published for this article.